TNW: A Promising Drug Candidate for Cancer and Neurodegenerative Diseases

Target Name: TNN

NCBI ID: G63923

Content of Review Report on TNN Target / Biomarker

TNN

TNW: A Promising Drug Candidate for Cancer and Neurodegenerative Diseases

TNW (TNW-112) is a small molecule inhibitor of the protein kinase PDGFR-尾, which is a non-coding RNA-protein hybrid that is involved in a variety of cellular processes, including cell growth, differentiation, and survival. PDGFR-尾 is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

TNW is currently being investigated as a potential drug candidate for the treatment of various cancers, including lung cancer, breast cancer, and colorectal cancer. In preclinical studies, TNW has been shown to inhibit the growth and survival of cancer cells, including human tumor samples, and to induce cell death, either through apoptosis or through a process called DNA damage-inducible cell death (DNDC).

One of the reasons why TNW is considered a promising drug candidate is its ability to selectively target PDGFR-尾, which is overexpressed in many types of cancer. This is because PDGFR-尾 is a protein that is expressed in high levels in many different types of cancer, including tumors, and is involved in the formation of multiple signaling pathways that promote cancer growth and survival. By inhibiting PDGFR-尾, TNW can inhibit the formation of these signaling pathways and potentially lead to the regression of cancer tumors.

Another reason why TNW is being investigated as a potential drug is its potential to be a once-daily treatment. Because TNW is a small molecule, it is easy to administer and can be taken once-daily, which could make it an attractive treatment option for patients who are experiencing chronic symptoms or who have limited treatment options.

In addition to its potential as a cancer treatment, TNW has also been shown to have potential in treating neurodegenerative diseases. PDGFR-尾 is involved in the formation of multiple signaling pathways that contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. By inhibiting PDGFR-尾, TNW may be able to treat neurodegenerative diseases and potentially slow down or stop their progression.

While the development of TNW as a drug candidate is still in its early stages, it is clear that it has the potential to be a valuable tool for the treatment of a variety of diseases. Further research is needed to determine its safety and effectiveness, and to identify the best ways to administer it to patients. However, if TNW is shown to be safe and effective in clinical trials, it could be an attractive treatment option for patients who are suffering from cancer or other neurodegenerative diseases.

Protein Name: Tenascin N

Functions: Extracellular matrix protein that seems to be a ligand for ITGA8:ITGB1, ITGAV:ITGB1 and ITGA4:ITGB1 (By similarity) (PubMed:17909022). Involved in neurite outgrowth and cell migration in hippocampal explants (By similarity). During endochondral bone formation, inhibits proliferation and differentiation of proteoblasts mediated by canonical WNT signaling (By similarity). In tumors, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells (PubMed:19884327). Expressed in most mammary tumors, may facilitate tumorigenesis by supporting the migratory behavior of breast cancer cells (PubMed:17909022)

The "TNN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets